Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct;13(24):2137-2149.
doi: 10.2217/fon-2017-0183. Epub 2017 Jul 31.

Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer

Sara López-Tarruella  1 , Yolanda Jerez  1 , Iván Márquez-Rodas  1 , Isabel Echavarria  1 , Miguel Martin  2
Affiliations
Review

Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer

Sara López-Tarruella et al. Future Oncol. 2017 Oct.

Abstract

CDK4/6 inhibitors are a promising new class of drugs for hormone-receptor-positive breast cancer and have been shown to overcome and delay hormone resistance in advanced breast cancer. Ribociclib, a selective oral inhibitor of CDK4/6, was approved by the US FDA for first-line treatment of hormone-receptor-positive/HER2-negative metastatic breast cancer. This review summarizes the clinical evidence available for ribociclib, from preclinical data to the pivotal studies, with a special focus on toxicity and its management. In addition, this article reviews potential new combinations under study, as well as ongoing clinical trials both in the metastatic and early setting. Finally, this review compares ribociclib activity and toxicity with those of the drugs of the same class (palbociclib and abemaciclib).

Keywords: CDK4/6 inhibitor; LEE011; advanced breast cancer; fulvestrant; hormone receptor positive; letrozole; ribociclib; tamoxifen.

PubMed Disclaimer

MeSH terms